Kestra Medical Technologies stock rating reiterated by Piper Sandler

Kestra Medical Technologies (KMTS) reported robust Q4 FY25 results, with revenue up 71% to $17.2 million and a gross margin of 44.3%, both exceeding analyst expectations. Despite a significant adjusted EBITDA loss of $20.3 million, highlighting ongoing profitability challenges, analysts like Piper Sandler and Stifel reiterated positive ratings, citing strong top-line momentum, conservative FY26 sales guidance of $85 million, and increasing market share in the wearable cardioverter defibrillator (WCD) market.

Analysis

Kestra Medical Technologies (KMTS) reported a mixed but fundamentally strong fiscal fourth-quarter 2025, characterized by significant top-line acceleration offset by continued unprofitability. Revenue grew an impressive 71% year-over-year to $17.2 million, surpassing consensus estimates, driven by a 43% increase in ASSURE prescription volume. The company also demonstrated operational leverage with a gross margin of 44.3%, which exceeded expectations due to a favorable patient mix. However, this growth came at a cost, as higher-than-anticipated operating expenses led to a substantial adjusted EBITDA loss of $20.3 million and a negative EPS of -2.21. Despite these losses, analyst sentiment from firms like Piper Sandler and Stifel remains positive, with both reiterating Buy/Overweight ratings and price targets ($28.00 and $27.00 respectively) that suggest significant upside from the current $15.22 stock price. This optimism is underpinned by a belief that the company's fiscal 2026 sales guidance of $85 million is conservative and that KMTS will continue to capture share in the $1 billion domestic wearable cardioverter defibrillator (WCD) market, a thesis supported by a newly secured sole source payer contract and plans to double its sales force.

Key Decisions for Investors

• Growth-focused investors may consider the current valuation an attractive entry point, given the 71% revenue growth, conservative forward guidance, and strong analyst price targets.
• Investors should exercise caution regarding the significant adjusted EBITDA loss of $20.3 million, and closely monitor the company's cash burn and progress towards profitability in subsequent quarters.
• The successful expansion of the sales force and its direct impact on prescription volume are critical catalysts to watch, as they are central to the company's market share growth thesis.
• The new sole source payer contract serves as a key validation of Kestra's technology; future announcements of similar contracts would be a strong positive signal for the company's competitive position and revenue quality.